Effect of anti-CD4 monoclonal antibody combined with human CTLA4Ig on the survival of hamster liver and heart xenografts in Lewis rats.

Yin DP, Sankary HN, Chong AS, Blinder L, Ma LL, Williams JW
Transplantation. 1997 64 (2): 317-21

PMID: 9256194 · DOI:10.1097/00007890-199707270-00024

We investigated the effects of pretransplant anti-CD4 monoclonal antibody (mAb) combined with human (h) CTLA4Ig on the survival of hamster heart and liver xenografts. Pretransplant anti-CD4 mAb (5 mg/kg x 4 days) or hCTLA4Ig (0.5 mg/rat on days 1, 3, and 5 after transplantation) treatment alone prolonged the survival of hamster liver xenografts in Lewis rats (mean survival time [MST]=10.5 days, n=6, and MST=9.0 days, n=5, respectively, compared with untreated Lewis recipients of hamster liver grafts, MST=6.0 days, n=6). The same regimen could not prevent hamster heart xenorejection. Pretransplant anti-CD4 mAb (5 mg/kg x 4 days) combined with hCTLA4Ig (0.5 mg/rat x 4) treatments increased survival of hamster liver xenograft fourfold (MST=24.2 days, n=5). The current results also show that IgG in the sera from Lewis recipients of hamster liver grafts treated with anti-CD4 mAb and hCTLA4Ig was threefold reduced at 6 days after transplantation compared with untreated Lewis rats. These results suggest a synergistic effect of anti-CD4 mAb combined with hCTLA4Ig in a liver xenograft transplantation model.

MeSH Terms (22)

Abatacept Animals Antibodies, Monoclonal Antigens, CD Antigens, Differentiation CD4 Antigens Cricetinae CTLA-4 Antigen Drug Therapy, Combination Graft Rejection Graft Survival Heart Transplantation Immunoconjugates Immunoglobulin Fc Fragments Liver Transplantation Male Mesocricetus Rats Rats, Inbred Lew Recombinant Fusion Proteins Transplantation, Heterologous Transplantation Conditioning

Connections (1)

This publication is referenced by other Labnodes entities:

Links